Glipizide and Metformin Hydrochloride Tablets
DEFINITION
Glipizide and Metformin Hydrochloride Tablets contain NLT 90.0% and NMT 110.0% of the labeled amounts of glipizide (C21H27N5O4S) and metformin hydrochloride (C4H11N5·HCl).
IDENTIFICATION
• A. Infrared Absorption 
197A
197A
Sample:
Transfer NLT 10 Tablets to a suitable container, add 10 mL of methanol, and shake to remove any Tablet coating. Drain the methanol, add 20 mL of water, and stir until the Tablets dissolve (1 h). Transfer the solution to a separatory funnel, and extract twice with 10-mL portions of chloroform, shaking for approximately 5 min. Transfer the lower organic layer into a beaker containing 3 to 4 g of anhydrous magnesium sulfate. Repeat the extraction of the solution in the separatory funnel two more times, each time using 20-mL portions of chloroform. Swirl the mixture in the beaker for 1 min. Filter, and collect the filtrate. Evaporate the solvent under vacuum, and dry the residue under vacuum for 4 h at 105
. Mound the residue onto a diamond cell.
. Mound the residue onto a diamond cell.
Acceptance criteria:
The IR spectrum exhibits maxima only at the same wavelengths as a similarly obtained spectrum of USP Glipizide RS.
• B.
The retention time of the major peak from the Sample solution corresponds to that of the Standard solution, as obtained in the Assay for Glipizide.
• C.
The retention time of the major peak from the Sample solution corresponds to that of the Standard solution, as obtained in the Assay for Metformin Hydrochloride.
ASSAY
• Glipizide
Solution A:
2.6 g/L of dibasic ammonium phosphate in water. Adjust with ammonium hydroxide to a pH of 8.0.
Solution B:
Acetonitrile, water, and Solution A (1:14:5)
Solution C:
Acetonitrile, water, and Solution A (2:1:1)
Diluent:
Acetonitrile and water (60:40)
Standard stock solution:
Transfer a weighed quantity of USP Glipizide RS to a suitable low-actinic volumetric flask. Dissolve first in acetonitrile, using 60% of the final volume, by sonicating for 20 min, then dilute with water to volume to obtain a solution having a concentration of 0.1 mg/mL of glipizide. [Note—The solution is stable for 2 weeks when stored at 5 and protected from light. ]
and protected from light. ]
Standard solution:
Transfer 25.0 mL of Standard stock solution to a 200-mL low-actinic volumetric flask. Add 75 mL of Diluent, and dilute with water to volume to obtain a solution having a known glipizide concentration of 0.0125 mg/mL. [Note—The solution is stable for 2 weeks when stored at 5 and protected from light. ]
and protected from light. ]
System suitability solution:
Transfer approximately 5 mg of USP Glipizide Related Compound A RS to a 500-mL volumetric flask, and fill halfway with acetonitrile. Sonicate for 30 min to dissolve, and dilute with acetonitrile to volume. Transfer 1 mL of this solution to a 50-mL low-actinic volumetric flask, and dilute with Standard solution to volume.
Sample solution:
Transfer NLT 5 Tablets to a suitable volumetric flask, and fill halfway with Diluent. Sonicate for 30 min, and shake vigorously for another 30 min to dissolve. Dilute with water to volume, and mix to obtain a solution with a final glipizide concentration of 0.0125 mg/mL. Pass a portion of this solution through a nylon or PVDF filter of 0.2-µm pore size, and use the filtrate. [Note—The solution is stable for 2 weeks when stored at 5 and protected from light. ]
and protected from light. ]
Mobile phase:
See the gradient table below.
| Time (min) |
Solution B (%) |
Solution C (%) |
|---|---|---|
| 0 | 100 | 0 |
| 3 | 100 | 0 |
| 18 | 0 | 100 |
| 20 | 0 | 100 |
| 22 | 100 | 0 |
| 30 | 100 | 0 |
Chromatographic system
Mode:
LC
Detector:
UV 223 nm
Column:
4.6-mm × 15-cm; 5-µm packing L7
Flow rate:
1 mL/min
Injection size:
50 µL
System suitability
Samples:
System suitability solution and Standard solution
[Note—The relative retention times for glipizide related compound A and glipizide are 0.92 and 1.0, respectively. ]
Suitability requirements
Resolution:
Greater than 1.2 between glipizide related compound A and glipizide, System suitability solution
Relative standard deviation:
Less than 2.0%, Standard solution
Analysis
Samples:
Standard solution and Sample solution
Calculate the percentage of C21H27N5O4S in the portion of Tablets taken:
Result = (rU/rS) × (CS/CU) × 100
| rU | = | = peak response from the Sample solution |
| rS | = | = peak response from the Standard solution |
| CS | = | = concentration of USP Glipizide RS in the Standard solution (mg/mL) |
| CU | = | = nominal concentration of glipizide in the Sample solution (mg/mL) |
Acceptance criteria:
90.0%–110.0%
• Metformin Hydrochloride
Solution A:
9.41 g/L of sodium 1-hexanesulfonate in water, and adjust with trifluoroacetic acid to a pH of 2.0 (50 mM hexanesulfonic acid solution)
Solution B:
Acetonitrile and water (40:60)
Mobile phase:
Solution A, Solution B, and water (3:2:5)
Diluent pH 2.0:
Acetonitrile, Solution A, and water (7:30:63)
Standard solution:
0.1 mg/mL of USP Metformin Hydrochloride RS in Diluent pH 2.0
System suitability solution:
5 µg/mL of USP Metformin Related Compound A RS in water. Pipet 0.5 mL of this solution into a 50-mL volumetric flask, and dilute with Standard solution to volume.
Sample solution:
Dilute a portion of the Sample solution, obtained as directed in the Assay for Glipizide, with Diluent pH 2.0, to obtain a solution having a concentration of 0.1 mg/mL of metformin hydrochloride.
Chromatographic system
Mode:
LC
Detector:
UV 218 nm
Column:
4.6-mm × 15-cm; 3.5-µm packing L11
Flow rate:
1 mL/min
Injection size:
25 µL
System suitability
Samples:
Standard solution and System suitability solution
[Note—The relative retention times for metformin related compound A and metformin are 0.26 and 1.0, respectively. ]
Suitability requirements
Resolution:
NLT 3.0 between metformin related compound A and metformin, System suitability solution
Relative standard deviation:
Less than 2.0%, determined from the metformin peak, Standard solution
Analysis
Samples:
Standard solution and Sample solution
Calculate the percentage of C4H11N5·HCl in each Tablet taken:
Result = (rU/rS) × (CS/CU) × 100
| rU | = | = peak response from the Sample solution |
| rS | = | = peak response from the Standard solution |
| CS | = | = concentration of USP Metformin Hydrochloride RS in the Standard solution (mg/mL) |
| CU | = | = nominal concentration of metformin hydrochloride in the Sample solution (mg/mL) |
Acceptance criteria:
90.0%–110.0%
PERFORMANCE TESTS
• Dissolution 711
711
Test 1
Medium:
0.05 M phosphate buffer, pH 6.8 ± 0.05. (Dissolve 12.96 g of monobasic potassium phosphate and 1.66 g of sodium hydroxide in approximately 400 mL of water, and dilute with water to 2000 mL. Adjust the pH, if necessary, with diluted sodium hydroxide); 1000 mL. [Note—Tight control of the pH is critical. ]
Apparatus 2:
50 rpm
Time:
45 min for glipizide, and 30 min for metformin hydrochloride.
Determination of glipizide:
Determine the amount of glipizide (C21H27N5O4S) dissolved as follows.
Solution A:
Dissolve approximately 3.4 g of monobasic potassium phosphate in approximately 800 mL of water. Adjust with 10 N sodium hydroxide solution to a pH of 6.0 ± 0.1. Dilute with water to 1000 mL.
Mobile phase:
Methanol and Solution A (13:12)
Standard stock solution:
Transfer 50 mg of USP Glipizide RS to a 1000-mL low-actinic volumetric flask, and dissolve in 100 mL of methanol. Dilute with Medium to volume, and sonicate for 5 min. [Note—This solution is stable for 7 days at 5 when protected from light. ]
when protected from light. ]
Standard solution:
Dilute the Standard stock solution with Medium to obtain a solution containing (L/1000) mg/mL, with L being the glipizide Tablet label claim, in mg.
Sample solution:
After the specified time, withdraw 10 mL of the solution under test. Pass the solution through a suitable PVDF filter of 0.45-µm pore size or a glass fiber filter of 1.0-µm pore size, discarding the first mL.
Chromatographic system
Mode:
LC
Detector:
UV 220 nm
Column:
4.6-mm × 15-cm; 5-µm packing L1
Flow rate:
1 mL/min
Injection size:
50 µL
System suitability
Sample:
Standard solution
Suitability requirements
Relative standard deviation:
NMT 2.0%
Analysis
Samples:
Standard solution and Sample solution
Record the chromatograms running for 8 min and measure the peak response for glipizide.
Calculate the percentage of C21H27N5O4S dissolved:
Result = (rU × CS × V × 100)/(rS × L)
| rU | = | = peak response from the Sample solution |
| CS | = | = concentration of glipizide in the Standard solution (mg/mL) |
| V | = | = volume of Medium, 1000 mL |
| rS | = | = peak response from the Standard solution |
| L | = | = label claim for glipizide (mg/Tablet) |
Determination of metformin hydrochloride:
Determine the amount of metformin hydrochloride dissolved by employing UV absorption at the wavelength of maximum absorbance at 233 nm on portions of the Sample solution, suitably diluted with Medium, if necessary, in comparison with a Standard solution having a known concentration of USP Metformin Hydrochloride RS in the same Medium.
Calculate the amount of C4H11N5·HCl dissolved:
Result = (AU × CS × V × 100)/(AS × L)
| AU | = | = absorbance from the Sample solution |
| CS | = | = concentration of the Standard solution (mg/mL) |
| V | = | = volume of Medium, 1000 mL |
| AS | = | = absorbance from the Standard solution |
| L | = | = label claim for metformin hydrochloride (mg/Tablet) |
Tolerances:
NLT 80% (Q) of the labeled amount of C21H27N5O4S is dissolved in 45 min. NLT 80% (Q) of the labeled amount of C4H11N5·HCl is dissolved in 30 min.
Test 2:
If the product complies with this test, the labeling indicates that the product meets USP Dissolution Test 2.
Medium:
0.05 M phosphate buffer, pH 6.8; 1000 mL
Apparatus 2:
50 rpm
Time:
60 min for both metformin hydrochloride and glipizide
pH 6.0 buffer solution:
4.3 g/L of octanesulfonic acid sodium salt and 6.9 g/L of monobasic monohydrate sodium phosphate in water, adjusted with diluted sodium hydroxide to a pH of 6.00 ± 0.05
Glipizide standard stock solution:
0.05 mg/mL of USP Glipizide RS in methanol
Standard solution:
Transfer a quantity of USP Metformin Hydrochloride RS to a volumetric flask, add a suitable aliquot of Glipizide standard stock solution, and dilute with Medium to obtain a final concentration of (L/1000) mg/mL, where L is the Tablet label claim for both metformin hydrochloride and glipizide, in mg.
Sample solution:
Pass a portion of the solution under test through a suitable polyethersulfone filter of 0.45-µm pore size, discarding the first few mL.
Mobile phase:
Methanol and pH 6.0 buffer solution (1:1)
Chromatographic system
Mode:
LC
Detector:
UV 260 nm
Sample compartment chiller:
4
Column:
4.6-mm × 25-cm; packing L1
Flow rate:
1.0 mL/min
Injection size:
20 µL
System suitability
Sample:
Standard solution
Suitability requirements
Resolution:
NLT 2 between the glipizide and metformin hydrochloride peaks
Relative standard deviation:
NMT 2.0% for both glipizide and metformin hydrochloride
Analysis:
Calculate the percentages of C21H27N5O4S and C4H11N5·HCl dissolved:
Result = (rU/rS) × (CS/L) × V × 100
| rU | = | = peak response for glipizide or metformin hydrochloride from the Sample solution |
| rS | = | = peak response for glipizide or metformin hydrochloride from the Standard solution |
| CS | = | = concentration of glipizide or metformin hydrochloride in the Standard solution (mg/mL) |
| L | = | = label claim for glipizide or metformin hydrochloride (mg/Tablet) |
| V | = | = volume of Medium, 1000 mL |
Tolerances:
NLT 80% (Q) of the labeled amounts of C21H27N5O4S and C4H11N5·HCl is dissolved.
• Uniformity of Dosage Units 905:
Meet the requirements
905:
Meet the requirements
IMPURITIES
Organic Impurities
• Procedure 1: Glipizide
Solution A, Solution B, Solution C, Sample solution, and Chromatographic system:
Prepare as directed in the Assay for Glipizide.
Analysis
Sample:
Sample solution
Calculate the percentage of glipizide related compound A (approximate relative retention time 0.92) and other individual impurities in the portion of Tablets taken:
Result = (rU/rT) × (1/F) × 100
| rU | = | = peak response of each impurity |
| rT | = | = sum of all the peak responses |
| F | = | = relative response factor for each impurity equal to 1.4 for glipizide related compound A and 1.0 for all other peaks |
Acceptance criteria
Glipizide related compound A:
NMT 2.0%
Individual impurities:
NMT 0.5% of any other individual glipizide related impurity (eluting after approximately 8 min)
Total impurities:
NMT 1.0%, excluding glipizide related compound A. [Note—Disregard the broad peak due to metformin that elutes before 8 min. Disregard any peak observed in the blank, and disregard any peak less than 0.05%. ]
• Procedure 2: Metformin Hydrochloride
Solution A, Solution B, Mobile phase, Sample solution, and Chromatographic system:
Prepare as directed in the Assay for Metformin Hydrochloride.
Analysis
Sample:
Sample solution
Calculate the percentage of each impurity in the portion of Tablets taken:
Result = (rU/rT) × 100
| rU | = | = peak response for each impurity |
| rT | = | = sum of all the peak responses |
Acceptance criteria
Individual impurities:
NMT 0.1%
Total impurities:
NMT 0.5%
[Note—Disregard any peak less than 0.05%. Disregard any peak observed in the blank. ]
ADDITIONAL REQUIREMENTS
• Packaging and Storage:
Preserve in well-closed containers, and store at controlled room temperature.
• Labeling:
When more than one Dissolution test is given, the labeling states the Dissolution test used only if Test 1 is not used.
• USP Reference Standards 11
11
USP Glipizide RS 
') + '&img=../../images/v35300/cas-29094-61-9.gif',600,500);)
USP Glipizide Related Compound A RS
N-{2-[(4-Aminosulfonyl)phenyl]ethyl}-5-methyl-pyrazinecarboxamide.
C14H16N4O3S 320.37
N-{2-[(4-Aminosulfonyl)phenyl]ethyl}-5-methyl-pyrazinecarboxamide.
C14H16N4O3S 320.37
USP Metformin Hydrochloride RS
') + '&img=../../images/v35300/cas-1115-70-4.gif',600,500);)
USP Metformin Related Compound A RS
1-Cyanoguanidine.
1-Cyanoguanidine.
Auxiliary Information—
Please check for your question in the FAQs before contacting USP.
| Topic/Question | Contact | Expert Committee |
|---|---|---|
| Monograph | Elena Gonikberg, Ph.D.
Principal Scientific Liaison 1-301-816-8251 |
(SM32010) Monographs - Small Molecules 3 |
| 711 |
Margareth R.C. Marques, Ph.D.
Senior Scientific Liaison 1-301-816-8106 |
(GCDF2010) General Chapters - Dosage Forms |
| Reference Standards | RS Technical Services 1-301-816-8129 rstech@usp.org |
USP35–NF30 Page 3339
Pharmacopeial Forum: Volume No. 32(4) Page 1076